在接受52周secukinumab或adalimumab治疗的银屑病性关节炎（PsA）患者中，评估着骨间炎治疗反应，包括解析时间和多个着骨间炎检测工具的数据。在EXCEED研究的这个事后分析中，根据Leeds着骨间炎指数（LEI）和加拿大强直性脊柱炎研究协会着骨间炎指数（SPARCC）评估着骨间炎基线存在或不存在的患者接受标签剂量的secukinumab 300mg或adalimumab 40mg分组。采用非反应者插值法评估效果，以达到着骨间炎解析（LEI / SPARCC = 0），Kaplan-Meier分析时间至解析，并根据其他结果采用现有数据。根据LEI评估，基线有498名患者中有58.5％（853名患者中632名有74.1％）着骨间炎。基线有着骨间炎的患者通常具有更高的疾病活动性。在第24周（secukinumab：LEI / SPARCC，49.6％/ 45.8％;adalimumab：LEI / SPARCC，43.6％/ 43.5％）和52周（secukinumab：LEI / SPARCC，60.7％/ 53.2％;adalimumab：LEI / SPARCC，55.3％/ 51.4％），secukinumab或adalimumab接受者均达到LEI和SPARCC的解析率类似，并且平均着骨间炎解析时间相似。两种药物在个体着骨间炎部位上的改善情况相似。在52周时，使用secukinumab或adalimumab解析着骨间炎与生活质量的改善有关。与肿瘤坏死因子α的抑制相比，secukinumab通过抑制白细胞介素17同样降低了临床着骨间炎。ClinicalTrials.gov，NCT02745080。©作者（们）2023年。由英国风湿病学会代表牛津大学出版。

To evaluate enthesitis treatment response, including time to resolution and data from multiple enthesitis instruments, in patients with psoriatic arthritis (PsA) treated with secukinumab or adalimumab for 52 weeks.In this post hoc analysis of the EXCEED study, patients receiving secukinumab 300 mg or adalimumab 40 mg per the label were grouped by presence or absence of baseline enthesitis based on the Leeds Enthesitis Index (LEI) and the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Efficacy was assessed according to several enthesitis-related instruments using nonresponder imputation for the achievement of enthesitis resolution (LEI/SPARCC = 0), Kaplan-Meier analysis for time to resolution, and as-observed data for other outcomes.Enthesitis was present at baseline in 498 of 851 patients (58.5%) as assessed by LEI and in 632 of 853 patients (74.1%) as assessed by SPARCC. Patients with baseline enthesitis generally presented with greater disease activity. Similar proportions of patients receiving secukinumab or adalimumab achieved resolution of LEI and SPARCC at Weeks 24 (secukinumab: LEI/SPARCC, 49.6%/45.8%; adalimumab: LEI/SPARCC, 43.6%/43.5%) and 52 (secukinumab: LEI/SPARCC, 60.7%/53.2%; adalimumab: LEI/SPARCC, 55.3%/51.4%), with comparable mean time to enthesitis resolution. Improvements were similar for both drugs at individual enthesitis sites. Resolution of enthesitis with secukinumab or adalimumab was associated with improvements in quality of life at week 52.Secukinumab and adalimumab showed similar efficacy, including time to resolution, with respect to resolution of enthesitis. Inhibition of interleukin 17 with secukinumab reduced clinical enthesitis similarly to tumor necrosis factor alpha inhibition.ClinicalTrials.gov, NCT02745080.© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.